Clinical Interventional Oncology Symposium And Integrative Healthcare Symposium

摘要

The Role of Y-90 for Neuroendocrine Tumors: Overall survival rates among patients with neuroendocrine tumors (NETs) treated with transarterial radioembolization with Y-90, a beta-emitting radionuclide, appear to be equal to rates for those treated via transarterial chemoembolization (FACE) or transarterial embolization (TAE). Toxicity is lower for Y-90, however, and unlike TACE and TAE, Y-90 radioembolization can be performed as an outpatient procedure.Both TAE and TACE reduce blood flow to NETs, leading to tumor ischemia and necrosis. Delivery of Y-90-bonded resin or glass microspheres leads to both embolization of vasculature and exposure of tumor tissue to the beta-emitting radionuclide. Y-90 radioembolization (also known as selective internal radiation therapy) is performed via transfemoral or transradial catheterization of the hepatic artery to the tumor vasculature. Treatment with Y-90, Dr. Clark said, is indicated for progressive, large, or symptomatic NETs, tumors that are functioning (producing secretions that lead to clinical symptoms), and/or tumors with mass effect (compression of adjacent organs or tissues). "Embolization does quite well, particularly for early-stage, well-differentiated G1 [grade] tumors," he said.